Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy

Chih-Chung ChengHung-Chieh YehPei-Wen SuChien-Lin HoSheng-Chi Changa Department of Surgery,China Medical University Hospital,Taichung,Taiwanb Division of Nephrology,Department of Internal Medicine,China Medical University Hospital,Taichung,Taiwanc Department of Nursing,China Medical University Hospital,Taichung,Taiwand Division of Colorectal Surgery,Department of Surgery,China Medical University Hospital,Taichung,Taiwan

DOI: https://doi.org/10.1080/02656736.2024.2304250

2024-02-13

International Journal of Hyperthermia

Abstract:Purpose Cisplatin is commonly prescribed in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. Acute kidney injury (AKI) is regarded as a common complication after HIPEC combined with cytoreductive surgery (CRS). However, post-HIPEC chronic kidney disease (CKD) is scarce and less investigated. This study aims to investigate the incidence of CKD following cisplatin-based HIPEC and to analyse the associated risk factors.

oncology,radiology, nuclear medicine & medical imaging

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the incidence of chronic kidney disease (CKD) after cisplatin - based hyperthermic intraperitoneal chemotherapy (HIPEC) and its related risk factors. Specifically, the study aims to:

1. **Evaluate the incidence of CKD after cisplatin - based HIPEC**: By retrospectively analyzing the data of 55 patients who received cytoreductive surgery (CRS) and cisplatin - based HIPEC from January 2016 to August 2021, the researchers hope to understand the occurrence of CKD in these patients.

2. **Analyze the risk factors related to the occurrence of CKD**: Through univariate and multivariate analyses, the researchers attempt to determine which factors are related to the occurrence of CKD after cisplatin - based HIPEC. The factors considered in the study include the patient's demographic characteristics, comorbidities, surgical information, postoperative management, and complications, etc.

### Research background
- **Acute kidney injury (AKI)**: One of the common complications after cisplatin - based HIPEC, but there are few studies on its long - term effects, especially on its progression to chronic kidney disease (CKD).
- **Nephrotoxicity of cisplatin**: Cisplatin is a known nephrotoxic chemotherapeutic drug. Although it is considered to have limited systemic diffusion when used in HIPEC, there is still a risk of kidney injury.
- **Other risk factors**: Including high body temperature, intraoperative complications, diabetes, etc. These factors may increase the risk of CKD.

### Main findings
- **Incidence of AKI**: Among 55 patients, 24 (43.6%) patients developed AKI within the first week after surgery.
- **Incidence of CKD**: Among 24 AKI patients, 17 (70.8%) patients had further deterioration of renal function within 1 - 2 weeks after surgery and stabilized within 1 month, meeting the criteria for CKD.
- **Main risk factors**:
- **The highest intraoperative body temperature exceeding 38.5°C**: Multivariate regression analysis shows that this factor significantly increases the risk of CKD (OR = 6.40).
- **The use of parecoxib during surgery**: Multivariate regression analysis shows that this factor also significantly increases the risk of CKD (OR = 4.39).

### Conclusions
- **The use of parecoxib during surgery**: The use of parecoxib during cisplatin - based HIPEC is identified as an important risk factor for postoperative CKD, and clinicians should use it with caution.
- **Maintaining intraoperative body temperature**: Keeping the intraoperative body temperature below 38.5°C may help reduce the risk of CKD development.
- **Preventive measures**: Identifying and preventing specific risk factors are crucial for improving the long - term renal function of patients receiving cisplatin - based HIPEC.

Through these findings, the study emphasizes the importance of identifying and managing risk factors during cisplatin - based HIPEC to reduce the occurrence of postoperative renal function impairment.